RU2672596C2 - Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе - Google Patents

Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе Download PDF

Info

Publication number
RU2672596C2
RU2672596C2 RU2014134420A RU2014134420A RU2672596C2 RU 2672596 C2 RU2672596 C2 RU 2672596C2 RU 2014134420 A RU2014134420 A RU 2014134420A RU 2014134420 A RU2014134420 A RU 2014134420A RU 2672596 C2 RU2672596 C2 RU 2672596C2
Authority
RU
Russia
Prior art keywords
microparticles
coating
drug
thickness
composite material
Prior art date
Application number
RU2014134420A
Other languages
English (en)
Russian (ru)
Other versions
RU2014134420A (ru
Inventor
Дэвид А. МАРШ
Хонгвен Ма РИВЕРЗ
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2014134420A publication Critical patent/RU2014134420A/ru
Application granted granted Critical
Publication of RU2672596C2 publication Critical patent/RU2672596C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2014134420A 2012-01-23 2013-01-22 Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе RU2672596C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23
US61/589,681 2012-01-23
PCT/US2013/022466 WO2013112434A1 (en) 2012-01-23 2013-01-22 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation

Publications (2)

Publication Number Publication Date
RU2014134420A RU2014134420A (ru) 2016-03-20
RU2672596C2 true RU2672596C2 (ru) 2018-11-16

Family

ID=47630595

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014134420A RU2672596C2 (ru) 2012-01-23 2013-01-22 Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе

Country Status (17)

Country Link
US (5) US20130189369A1 (enExample)
EP (1) EP2806853B1 (enExample)
JP (1) JP6282231B2 (enExample)
KR (5) KR20140114892A (enExample)
CN (1) CN104136006B (enExample)
AU (3) AU2013212583A1 (enExample)
BR (1) BR112014017969A8 (enExample)
CA (1) CA2861348C (enExample)
DK (1) DK2806853T3 (enExample)
ES (1) ES2821526T3 (enExample)
HU (1) HUE050904T2 (enExample)
IL (2) IL233620A0 (enExample)
MX (1) MX364864B (enExample)
NZ (1) NZ627368A (enExample)
RU (1) RU2672596C2 (enExample)
WO (1) WO2013112434A1 (enExample)
ZA (1) ZA201405091B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
CN109310680B (zh) * 2016-06-30 2022-11-01 度瑞公司 长效配制物
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
BR112020000506A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4308106A4 (en) * 2021-03-15 2025-02-26 Oakwood Laboratories, Llc MICROSPHERE FORMULATIONS CONTAINING NALTREXONE AND METHODS OF PREPARING AND USING THE SAME
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN116869914A (zh) * 2023-05-30 2023-10-13 庄秉谚 无针注射系统的投递物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441732A (en) * 1990-06-15 1995-08-15 Allergan, Inc. Reversible gelation emulsion compositions and methods of use
EP1568359A1 (en) * 2002-12-04 2005-08-31 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
WO2007012974A2 (en) * 2005-07-22 2007-02-01 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
RU2316315C2 (ru) * 2001-09-14 2008-02-10 Новартис Аг Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения
US20100203151A1 (en) * 2007-06-25 2010-08-12 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1125577B1 (en) * 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441732A (en) * 1990-06-15 1995-08-15 Allergan, Inc. Reversible gelation emulsion compositions and methods of use
RU2316315C2 (ru) * 2001-09-14 2008-02-10 Новартис Аг Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
EP1568359A1 (en) * 2002-12-04 2005-08-31 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
WO2007012974A2 (en) * 2005-07-22 2007-02-01 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20100203151A1 (en) * 2007-06-25 2010-08-12 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ЧУЕШОВ В.И. Промышленная технология лекарств, том 1, Харьков, издательство НФАУ, 2002, с. 24, 1, 2 абзацы. *

Also Published As

Publication number Publication date
AU2017258895A1 (en) 2017-11-30
CA2861348A1 (en) 2013-08-01
CN104136006A (zh) 2014-11-05
KR20200133286A (ko) 2020-11-26
KR20200073292A (ko) 2020-06-23
US20240423922A1 (en) 2024-12-26
HK1204765A1 (en) 2015-12-04
BR112014017969A8 (pt) 2017-07-11
EP2806853A1 (en) 2014-12-03
NZ627368A (en) 2016-11-25
IL265620B (en) 2022-03-01
ZA201405091B (en) 2015-12-23
CN104136006B (zh) 2017-11-24
MX2014008857A (es) 2015-07-17
AU2019204957A1 (en) 2019-07-25
US20230390212A1 (en) 2023-12-07
US20240226022A1 (en) 2024-07-11
MX364864B (es) 2019-05-09
IL233620A0 (en) 2014-08-31
AU2013212583A1 (en) 2014-08-14
JP6282231B2 (ja) 2018-02-21
RU2014134420A (ru) 2016-03-20
AU2017258895B2 (en) 2019-04-18
KR102183727B1 (ko) 2020-11-27
IL265620A (en) 2019-05-30
HUE050904T2 (hu) 2021-01-28
CA2861348C (en) 2017-07-04
US20130189369A1 (en) 2013-07-25
WO2013112434A1 (en) 2013-08-01
KR20230104761A (ko) 2023-07-10
KR20220044379A (ko) 2022-04-07
US20200297650A1 (en) 2020-09-24
EP2806853B1 (en) 2020-07-08
JP2015504098A (ja) 2015-02-05
DK2806853T3 (da) 2020-09-28
BR112014017969A2 (enExample) 2017-06-20
KR20140114892A (ko) 2014-09-29
ES2821526T3 (es) 2021-04-26

Similar Documents

Publication Publication Date Title
AU2017258895B2 (en) Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
Ghasemiyeh et al. Hydrogels as drug delivery systems; pros and cons
JP5341172B2 (ja) 生分解性ポリマー担体中のクロニジン製剤
RU2440102C2 (ru) Системы доставки лекарственного средства внутрь глаза
CN111481513B (zh) 缓释微球药物递送系统及其制备方法
CN102552106A (zh) 延长缓释超过2个月的类固醇眼内植入物
JP2005538107A5 (ja) 注入可能な多モードポリマーのデポ組成物及びその使用
CN101951892A (zh) 使用氯压定和布比卡因治疗手术后疼痛的组合物和方法
CN102395401A (zh) 经由水凝胶塞的药物递送
CA2741252A1 (en) Drug delivery systems and methods for treating neovascularization
US20090148527A1 (en) Intraocular formulation
Patel et al. Biodegradable polymers: emerging excipients for the pharmaceutical and medical device industries
JP2019503352A (ja) 徐放性シクロスポリン添加微粒子
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
ES3006986T3 (en) Biodegradable compositions and implants
HK1204765B (en) Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
CN1969825A (zh) 一种氟尿嘧啶及其增效剂的缓释剂
HK40115702A (en) Single solution hydrogels with covalent bonding formed in situ, composition design and medical procedures using the hydrogels
CN101023919A (zh) 一种抗实体肿瘤缓释剂